Entwicklung und Erprobung von Leichtflugzeugen

EQS-News: Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 1.05 per share

Retrieved on: 
torsdag, juni 15, 2023
Dronabinol, Botanischer Garten für Arznei- und Gewürzpflanzen Oberholz, Annual, Supervisory board, Mass meeting, Aggression, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, EUR, EBITDA, Institut für Integrierte Produktion Hannover, Acquisition, Pharma, Entwicklung und Erprobung von Leichtflugzeugen, Annual general meeting, Rope, Management

Grünwald, 14 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2023 Annual General Meeting.

Key Points: 
  • Grünwald, 14 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2023 Annual General Meeting.
  • 22.53% of the share capital was in attendance at the Annual General Meeting, which was held in person.
  • At the recommendation of the Board of Management, the Annual General Meeting resolved to distribute a dividend of EUR 1.05 per share.
  • The total distribution amounts to EUR 56.5 million, representing a distribution ratio of approximately 42%.

Global Bioactive Peptide Market Report 2022: Increasing R&D by Leading Players Driving Growth - ResearchAndMarkets.com

Retrieved on: 
fredag, november 11, 2022
Biotechnology, Health, Other Health, Pulmonary edema, Cerebral edema, Entwicklung und Erprobung von Leichtflugzeugen, Industry, Rheumatoid arthritis, US, Region, Protein, Conditional sentence, Cardiovascular disease, Cancer, Peptide, Research, Food, Market share, CAGR, Infection, Diabetes, Par value, Growth, Short bowel syndrome, Marketing, Nutrient, Inhalation, Fine chemical

The "Bioactive Peptide Market, by Source, by Therapeutic Area, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bioactive Peptide Market, by Source, by Therapeutic Area, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The bioactive peptides are ingredients that provide nutritive value to the food by adding protein and other important nutrients.
  • Therefore, bioactive peptides are used as treatment therapy for most of the functional disorders such as irritable bowel disease, which is expected to drive the market growth.
  • Increasing research and development by key market players for the treatment of pulmonary edema and rheumatoid arthritis is expected to drive growth of the global bioactive peptide market over the forecast period.

DGAP-News: EQT AB: H&F geht Partnerschaft mit EQT Private Equity ein für verbessertes freiwilliges Übernahmeangebot der Zorro Bidco für die zooplus AG zu einem erhöhten, finalen Angebotspreis von EUR480 je Aktie

Retrieved on: 
måndag, oktober 25, 2021
Treffen, Hellman & Friedman, Partner, Internet, Das Kapital, Zu, EQT, CEO, Autumn, Entwicklung und Erprobung von Leichtflugzeugen, Software, Unternehmen Michael, Gemeinschaft and Gesellschaft, Powder metallurgy, Financial adviser, Animal, Rope

EQT AB: H&F geht Partnerschaft mit EQT Private Equity ein fr verbessertes freiwilliges bernahmeangebot der Zorro Bidco fr die zooplus AG zu einem erhhten, finalen Angebotspreis von EUR480 je Aktie

Key Points: 
  • EQT AB: H&F geht Partnerschaft mit EQT Private Equity ein fr verbessertes freiwilliges bernahmeangebot der Zorro Bidco fr die zooplus AG zu einem erhhten, finalen Angebotspreis von EUR480 je Aktie
    The issuer is solely responsible for the content of this announcement.
  • fr verbessertes freiwilliges bernahmeangebot der Zorro Bidco fr die zooplus AG zu einem erhhten, finalen Angebotspreis von EUR 480 je Aktie
    Die Partnerschaft zwischen Hellman & Friedman und EQT Private Equity bietet den zooplus-Aktionren hhere Transaktionssicherheit zu verbesserten wirtschaftlichen Bedingungen.
  • das "Zorro-Angebot") fr alle ausstehenden Aktien der zooplus AG ("zooplus" oder die "Gesellschaft") zu einer erhhten, finalen Bargegenleistung von EUR 480 je zooplus-Aktie (das "Erhhte Angebot") eingehen.
  • August 2021 hat Zorro Bidco, eine Holdinggesellschaft, die derzeit durch von H&F beratene Fonds kontrolliert wird, ihre Absicht angekndigt, ein freiwilliges ffentliches bernahmeangebot fr zooplus zu unterbreiten.